PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans Nov 13, 2020 Poster 746.5 KB Presentation Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment Nov 13, 2020 Poster 664.1 KB Presentation In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist Jul 30, 2020 Publication 1.7 MB PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model Apr 09, 2020 Poster 931.5 KB
PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans Nov 13, 2020 Poster 746.5 KB Presentation
Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment Nov 13, 2020 Poster 664.1 KB Presentation
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist Jul 30, 2020 Publication 1.7 MB
PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model Apr 09, 2020 Poster 931.5 KB
